Articles

A report, launched by Takeda UK, has shown that despite the increase in media attention, COVID-19 has had little positive impact on the perception of pharmaceutical companies. 

Report Reveals the Pandemic had Little Positive Impact on Pharma Reputation

EUA marks a milestone in COVID-19 vaccine development and is hailed as a turning point in pandemic fight. 

First COVID-19 Vaccine Heads to US Patients

The company will expand the site to include six new containment isolators and a product development manufacturing laboratory.

Vectura to Incorporate HPAPI Capabilities into UK Facility 

Through the acquisition, AstraZeneca will work with Alexion’s R&D team to build up Alexion's pipeline of 11 molecules across more than 20 clinical-development programs in several indications.

AstraZeneca to Acquire Alexion for $39 Billion

Through the acquisition Gilead will gain access to Hepcludex (bulevirtide) for the treatment of chronic HDV infection in adults with compensated liver disease.

Gilead to Acquire MYR for $1.4 Billion 

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Success in combatting the pandemic depends on the ability of manufacturers to quickly and efficiently produce and distribute the huge quantities of vaccines demanded by the United States government and public health organizations around the world. 

Vaccine Scale-up and Production Key to Combatting Pandemic

The acquisition will enhance Boehringer Ingelheim’s cancer cell-directed therapies portfolio and will complement its existing capabilities in antigen discovery and antibody and T-cell engager technologies. 

Boehringer Ingelheim to Acquire NBE-Therapeutics for $1.4 Billion

Committee recommends Emergency Use Authorization of first mRNA-based COVID-19 vaccine; FDA approval is pending.

Pfizer-BioNTech Vaccine Moves Closer to EUA

ISPE and Gilead Sciences have partnered up for the establishment of an internship program.

ISPE Foundation and Gilead Sciences Partner on Internship Program

The European Commission has granted a license for the use of inclisiran (Leqvio) as a treatment of primary hypercholesterolemia or mixed dyslipidaemia in adult patients.

News